Posted by Michael Wonder on 15 Dec 2023
Abbisko Therapeutics announces that US FDA has granted fast track designation for its CSF-1R inhibitor pimicotinib (ABSK021)
13 December 2023 - Abbisko Therapeutics today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation by the US FDA for the treatment of tenosynovial giant cell tumour patients that are not amenable to surgery.
Previously, pimicotinib was granted the breakthrough therapy designation by the US FDA for tenosynovial giant cell tumour in January 2023.
